EN DE
Watch iX Biopharma Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

iX Biopharma Ltd (42C) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of iX Biopharma Ltd stock S$0.26, price S$0.51, that is 48.1% below the price, quality 41 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare SG · ISIN SG1BD9000009

IB iX Biopharma Ltd logo Thin data Nov 10, 2026

iX Biopharma Ltd

42C · SG
Very expensive, weak quality

Our calculation puts a fair price 48% below what the stock costs today.

Low debt
Quality 41/100
Mixed Growth (revenue 5y +31.5 %/yr in SGD)
Fair value 0.2623 SGD · Strongly overvalued
Loss-making · -116.6% net margin (TTM)
Negative free cash flow
Trails peers (1/9)
Narrow moat 8/100 · thin data
Thin data
Estimate
Watch iX Biopharma Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

0.6250 SGD 0.0160 SGD Fair Value 0.2623 SGD Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range 0.0160 SGD – 0.6250 SGD · fair‑value band 0.1967 SGD – 0.3279 SGD · the 0.5050 SGD price screens above the 0.2623 SGD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow iX Biopharma in your weekly email

Every Wednesday you see whether iX Biopharma is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

iX Biopharma Ltd., a specialty pharmaceutical and nutraceutical company, develops, manufactures, and commercializes therapies for the treatment of acute and breakthrough pain, and other health conditions in Singapore, the United States, China, Australia and internationally.

Show moreShow less

The company operates through Specialty Pharmaceutical and Nutraceutical segments. It offers Wafesil and Silcap for the treatment of male erectile dysfunction; as well as Hypera, a sublingual tetrahydrocannabinol wafer for chronic pain, anxiety, insomnia and other conditions.

The company is also developing Wafermine, a racemic ketamine sublingual wafer, which has completed phase-2 clinical trial for the treatment of complex regional pain syndrome, as well as psychiatric conditions, including depression; iXB 401, a sublingual semaglutide wafer that is in pre-clinical development for the treatment of Type 2 Diabetes and Obesity; SL-NAD+, a sublingual NAD+ wafer to increase the body's NAD+ levels, energy levels, and alertness.

In addition, it develops BnoX that is in a phase-1 clinical trial for moderate to severe pain; NAD+ for sarcopenia; and LumeniX, a sublingual glutathione wafer for skin brightening and immunity. iX Biopharma Ltd. was incorporated in 2004 and is headquartered in Singapore.

Stock analysis

iX Biopharma Ltd (42C) currently trades at 0.5050 SGD, while our estimate is 0.2623 SGD, 48% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 0.1967 SGD (bear) to 0.3279 SGD (bull), the price of 0.5050 SGD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

iX Biopharma Ltd reported revenue of 6.9M SGD in FY2026 versus 14.4M SGD in FY2022, a compound −16.9%/yr. Reported net income was −8.0M SGD in FY2026.

Key figures

Market cap 539M SGD (≈ $421M) Small · P/S ratio 72.0 · EPS (TTM) −0.0100 SGD · Net margin −117% · Return on equity −101% · Return on assets (EBIT) −35.8% (5-year average) · Operating margin −221% · Revenue (TTM) 6.9M SGD.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 19% below its 52-week high and 359% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −48%, 42C screens richer than that median.

Fair Value

Bear 0.1967 SGD Fair Value 0.2623 SGD Bull 0.3279 SGD
Price 0.5050 SGD · Downside -48.1%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 41/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 5
How much profit the company makes from its sales and capital
Quality Growth 60
Are margins and returns getting better?
Cashflow 10
Do the profits arrive as real cash?
Financial strength 93
Debt, balance sheet and risk of trouble
Investment 98
Does it invest with discipline instead of growing at any price?
Low Volatility 31
How calm the share price moves, does not count
Price momentum 77
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 88
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 30/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−11.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+31.5%
Start year 2021 (pandemic). Over 10 years: +1.7% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−577.6% (2021) → −138.7% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

42C screens overvalued: fair value 48% below the price. Compare with Merck KGaA →

Compare iX Biopharma Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 606 stocks

Beats the industry median on 1/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 41 · Bottom 25%
Fair Value upside −48.1% · Below median
Profitability
Return on assets −30.9% · Bottom 25%
Net margin (12 months) −116.6% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −6.6% · Below median
Balance sheet
Debt / equity 0.01× · Lowest 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 35.04× · Priciest 25%
P/S (12 months) 78.72× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 18
FUTURE (revenue growth)0 · sector 25
PAST (return on equity)0 · sector 25
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 31

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $82.46 $113.53 +38% vs 42C
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥48.55 ¥55.21 +14% vs 42C
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,905 ₹1,983 +4% vs 42C
Haleon plc HLN $9.06 $8.62 −5% vs 42C
Merck KGaA MRK €149.35 €109.18 −27% vs 42C
Galderma Group GALD CHF 188.55 CHF 109.80 −42% vs 42C
Takeda Pharmaceutical Company TAK $20.93 $11.34 −46% vs 42C
Teva Pharmaceutical Industries Limited TEVA $42.40 $20.74 −51% vs 42C
Sandoz Group SDZ CHF 83.38 CHF 39.70 −52% vs 42C
Divi's Laboratories Limited DIVISLAB ₹11,566 ₹1,567 −86% vs 42C

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

iX Biopharma Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "iX Biopharma Ltd Fair Value". https://www.fairvalue-calculator.com/stock/42C

Frequently asked questions

Is iX Biopharma Ltd (42C) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is 0.2623 SGD versus a price of 0.5050 SGD, about 48% lower (overvalued).
What is the fair value of 42C?
Our estimate for iX Biopharma Ltd is 0.2623 SGD (as of Nov 10, 2026), built from audited fundamentals. The current price: 0.5050 SGD.
What is the quality score of 42C?
iX Biopharma Ltd has a Quality Score of 41/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for iX Biopharma Ltd (42C)?
Our calculated price target is the estimate of 0.2623 SGD (as of Nov 10, 2026). Cautious scenario 0.1967 SGD, optimistic scenario 0.3279 SGD. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the iX Biopharma Ltd stock forecast for 2026?
Our estimate puts fair value at 0.2623 SGD, about 48% lower versus a price of 0.5050 SGD (overvalued). Cautious scenario 0.1967 SGD, optimistic scenario 0.3279 SGD. The calculation is refreshed regularly with new filings.
What is the revenue of iX Biopharma Ltd (42C)?
iX Biopharma Ltd reported trailing-twelve-month revenue of about 6.9M SGD (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of iX Biopharma Ltd (42C)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For iX Biopharma Ltd it is 0.2623 SGD per share (as of Nov 10, 2026), against a price of 0.5050 SGD.
Is iX Biopharma Ltd stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 42C trades above its calculated fair value: price 0.5050 SGD, fair value 0.2623 SGD, a gap of about −48% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 42C?
No. The price is what the market pays today (0.5050 SGD); the fair value is what the company's own numbers justify (0.2623 SGD). For iX Biopharma Ltd the two are 0.2427 SGD per share apart. That gap is exactly why we show both numbers side by side.
How much is iX Biopharma Ltd worth?
The market values iX Biopharma Ltd at about 539M SGD (market capitalisation, as of Nov 10, 2026). Per share that is 0.5050 SGD; our models calculate a fair value of 0.2623 SGD per share.
What do the bullish and bearish scenarios say about 42C?
Our models span a range for iX Biopharma Ltd: cautious scenario 0.1967 SGD, base 0.2623 SGD, optimistic 0.3279 SGD per share (as of Nov 10, 2026, price 0.5050 SGD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of iX Biopharma Ltd (42C)?
Balance-sheet figures for iX Biopharma Ltd (as of Nov 10, 2026): return on equity −101.4%, debt of 0.01 per unit of equity. They feed the Quality Score of 41/100, which measures business quality independently of the share price.
How far is 42C from its 52-week high?
iX Biopharma Ltd trades at 0.5050 SGD, about 19% below its 52-week high of 0.6250 SGD and 359% above the low of 0.1100 SGD (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of 0.2623 SGD is for.
Which stocks are comparable to iX Biopharma Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is iX Biopharma Ltd stock attractive at the current price?
The data as of Nov 10, 2026: price 0.5050 SGD, calculated fair value 0.2623 SGD (−48%), Quality Score 41/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. iX Biopharma Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of iX Biopharma Ltd (42C)?
The closing price on Nov 10, 2026 was 0.5050 SGD. Our estimate is 0.2623 SGD, about 48% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with iX Biopharma Ltd right now?
The price sits above even our optimistic bull case (0.3279 SGD). The favourable scenario is already priced in. Weak quality (41/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of iX Biopharma Ltd

How large is the market capitalisation of iX Biopharma Ltd (42C)?
The market capitalisation of iX Biopharma Ltd is 539M SGD (≈ $421M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of iX Biopharma Ltd (42C)?
The price-to-sales ratio of iX Biopharma Ltd is 72.0 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of iX Biopharma Ltd (42C)?
Earnings per share at iX Biopharma Ltd are −0.0100 SGD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of iX Biopharma Ltd (42C)?
The net margin of iX Biopharma Ltd is −117% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of iX Biopharma Ltd (42C)?
The return on equity (ROE) of iX Biopharma Ltd is −101% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of iX Biopharma Ltd (42C)?
On an EBIT basis the return on assets of iX Biopharma Ltd is −35.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of iX Biopharma Ltd (42C)?
The operating margin of iX Biopharma Ltd is −221% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at iX Biopharma Ltd (42C)?
Revenue at iX Biopharma Ltd is growing −6.6% versus a year earlier (3y avg +5.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does iX Biopharma Ltd (42C) generate?
The free cash flow of iX Biopharma Ltd is −7.6M SGD (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does iX Biopharma Ltd (42C) carry?
The net debt of iX Biopharma Ltd is 4.7M SGD (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch iX Biopharma Ltd in the live analysis

One click puts iX Biopharma Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.